Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
Abstract Objective This study aimed to investigate the correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerotic cardiovascular disease (ASCVD) in individuals with type 1 diabetes (T1D). Methods Adults with T1D (n = 659) were consecutively screened for...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-025-02764-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243510101344256 |
|---|---|
| author | Jonathan Mertens Jonas Weyler Eveline Dirinck Luisa Vonghia Wilhelmus J. Kwanten Luc F. Van Gaal Benedicte Y. De Winter Sven Francque Christophe De Block |
| author_facet | Jonathan Mertens Jonas Weyler Eveline Dirinck Luisa Vonghia Wilhelmus J. Kwanten Luc F. Van Gaal Benedicte Y. De Winter Sven Francque Christophe De Block |
| author_sort | Jonathan Mertens |
| collection | DOAJ |
| description | Abstract Objective This study aimed to investigate the correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerotic cardiovascular disease (ASCVD) in individuals with type 1 diabetes (T1D). Methods Adults with T1D (n = 659) were consecutively screened for liver steatosis via abdominal ultrasound. The presence of macrovascular disease (including coronary artery disease [CAD], peripheral artery disease [PAD], or ischaemic stroke [CVA, cerebrovascular accident]) was identified via electronic medical records. The 5- and 10-year risks of fatal/nonfatal ASCVD were assessed via the Steno Type 1 Risk Engine. Insulin resistance was assessed via the estimated glucose disposal rate (eGDR). Results The MASLD prevalence was 16.8%. The prevalence of composite ASCVD (18.9 vs. 6.8%, p < 0.001), CAD (9.9 vs. 4.7%, p = 0.031), PAD (9.0 vs. 2.2%, p < 0.001) and CVA (6.3 vs. 1.1%, p = 0.002) was greater in people with MASLD. The 5-year (7.8 [2.1–14.4] vs. 4.8 [1.6–12.0]%, p = 0.034) and 10-year (15.0 [4.1–26.8] vs. 9.4 [3.1–22.5]%, p = 0.035) risks of ASCVD were greater in those with MASLD. MASLD was associated with prevalent ASCVD (adjusted OR 4.26, 95% CI 1.79–10.11, p < 0.001), independent of age, sex, diabetes duration, smoking, statin use, LDL-cholesterol, the glomerular filtration rate, albuminuria, and metabolic syndrome. Conclusion MASLD is associated with both an increased prevalence of ASCVD and an increased calculated risk of fatal/nonfatal ASCVD in people with T1D. |
| format | Article |
| id | doaj-art-7a2df0e46dda489a8cfc993dcb6acb30 |
| institution | OA Journals |
| issn | 1475-2840 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj-art-7a2df0e46dda489a8cfc993dcb6acb302025-08-20T01:59:57ZengBMCCardiovascular Diabetology1475-28402025-05-0124111110.1186/s12933-025-02764-yIncreased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver diseaseJonathan Mertens0Jonas Weyler1Eveline Dirinck2Luisa Vonghia3Wilhelmus J. Kwanten4Luc F. Van Gaal5Benedicte Y. De Winter6Sven Francque7Christophe De Block8Department of Endocrinology, Diabetology and Metabolism, Antwerp University HospitalLaboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of AntwerpDepartment of Endocrinology, Diabetology and Metabolism, Antwerp University HospitalLaboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of AntwerpLaboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of AntwerpDepartment of Endocrinology, Diabetology and Metabolism, Antwerp University HospitalLaboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of AntwerpLaboratory of Experimental Medicine and Paediatrics and member of the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of AntwerpDepartment of Endocrinology, Diabetology and Metabolism, Antwerp University HospitalAbstract Objective This study aimed to investigate the correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) and atherosclerotic cardiovascular disease (ASCVD) in individuals with type 1 diabetes (T1D). Methods Adults with T1D (n = 659) were consecutively screened for liver steatosis via abdominal ultrasound. The presence of macrovascular disease (including coronary artery disease [CAD], peripheral artery disease [PAD], or ischaemic stroke [CVA, cerebrovascular accident]) was identified via electronic medical records. The 5- and 10-year risks of fatal/nonfatal ASCVD were assessed via the Steno Type 1 Risk Engine. Insulin resistance was assessed via the estimated glucose disposal rate (eGDR). Results The MASLD prevalence was 16.8%. The prevalence of composite ASCVD (18.9 vs. 6.8%, p < 0.001), CAD (9.9 vs. 4.7%, p = 0.031), PAD (9.0 vs. 2.2%, p < 0.001) and CVA (6.3 vs. 1.1%, p = 0.002) was greater in people with MASLD. The 5-year (7.8 [2.1–14.4] vs. 4.8 [1.6–12.0]%, p = 0.034) and 10-year (15.0 [4.1–26.8] vs. 9.4 [3.1–22.5]%, p = 0.035) risks of ASCVD were greater in those with MASLD. MASLD was associated with prevalent ASCVD (adjusted OR 4.26, 95% CI 1.79–10.11, p < 0.001), independent of age, sex, diabetes duration, smoking, statin use, LDL-cholesterol, the glomerular filtration rate, albuminuria, and metabolic syndrome. Conclusion MASLD is associated with both an increased prevalence of ASCVD and an increased calculated risk of fatal/nonfatal ASCVD in people with T1D.https://doi.org/10.1186/s12933-025-02764-yAtherosclerotic cardiovascular diseaseInsulin resistanceMASLDMetabolic syndromeType 1 diabetes |
| spellingShingle | Jonathan Mertens Jonas Weyler Eveline Dirinck Luisa Vonghia Wilhelmus J. Kwanten Luc F. Van Gaal Benedicte Y. De Winter Sven Francque Christophe De Block Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease Cardiovascular Diabetology Atherosclerotic cardiovascular disease Insulin resistance MASLD Metabolic syndrome Type 1 diabetes |
| title | Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease |
| title_full | Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease |
| title_fullStr | Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease |
| title_full_unstemmed | Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease |
| title_short | Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease |
| title_sort | increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with type 1 diabetes and metabolic dysfunction associated steatotic liver disease |
| topic | Atherosclerotic cardiovascular disease Insulin resistance MASLD Metabolic syndrome Type 1 diabetes |
| url | https://doi.org/10.1186/s12933-025-02764-y |
| work_keys_str_mv | AT jonathanmertens increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT jonasweyler increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT evelinedirinck increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT luisavonghia increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT wilhelmusjkwanten increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT lucfvangaal increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT benedicteydewinter increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT svenfrancque increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease AT christophedeblock increasedprevalenceandriskofatheroscleroticcardiovasculardiseaseinindividualswithtype1diabetesandmetabolicdysfunctionassociatedsteatoticliverdisease |